25 XP   0   0   10

Cyclo Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Cyclo Therapeutics Inc together

PenkeI guess you are interested in Cyclo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cyclo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cyclo Therapeutics Inc

I send you an email if I find something interesting about Cyclo Therapeutics Inc.

Quick analysis of Cyclo Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Cyclo Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.17
Expected worth in 1 year
$0.31
How sure are you?
38.5%

+ What do you gain per year?

Total Gains per Share
$0.14
Return On Investment
11.1%

For what price can you sell your share?

Current Price per Share
$1.26
Expected price per share
$1.1308 - $1.45
How sure are you?
50%

1. Valuation of Cyclo Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$1.26

Intrinsic Value Per Share

$-6.19 - $-4.77

Total Value Per Share

$-6.03 - $-4.61

2. Growth of Cyclo Therapeutics Inc (5 min.)




Is Cyclo Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$4.7m$7.2m-$6.8m-1,536.2%

How much money is Cyclo Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$5m$40.7b-$40.7b-812,031.2%
Net Profit Margin-2,504.7%20,889,147.8%--

How much money comes from the company's main activities?

3. Financial Health of Cyclo Therapeutics Inc (5 min.)




What can you expect buying and holding a share of Cyclo Therapeutics Inc? (5 min.)

Welcome investor! Cyclo Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Cyclo Therapeutics Inc.

What can you expect buying and holding a share of Cyclo Therapeutics Inc?

First you should know what it really means to hold a share of Cyclo Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Cyclo Therapeutics Inc is $1.26. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cyclo Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cyclo Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.17. Based on the TTM, the Book Value Change Per Share is $0.04 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cyclo Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.20-15.6%-0.17-13.9%-0.13-10.7%-0.12-9.2%-0.07-5.7%
Usd Book Value Change Per Share0.2016.1%0.042.8%-0.13-10.3%0.010.5%0.000.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.2016.1%0.042.8%-0.13-10.3%0.010.5%0.000.2%
Usd Price Per Share1.59-1.36-2.12-2.47-1.53-
Price to Earnings Ratio-2.02--1.96--4.40--5.13--5.97-
Price-to-Total Gains Ratio7.86-9.50--18.40--6.58--6.15-
Price to Book Ratio9.60--28.71-19.54-1.43-6.24-
Price-to-Total Gains Ratio7.86-9.50--18.40--6.58--6.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.26
Number of shares793
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.040.01
Usd Total Gains Per Share0.040.01
Gains per Quarter (793 shares)27.775.20
Gains per Year (793 shares)111.0820.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1011110102111
2022221204232
3033332306253
4044443408374
50555545010495
606666560125116
707787670146137
808898780166158
9010009890187179
100111111000208200

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.038.00.02.6%23.065.00.026.1%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%7.013.00.035.0%15.024.00.038.5%48.040.00.054.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.039.00.0%0.00.088.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%7.013.00.035.0%15.024.00.038.5%48.040.00.054.5%

Fundamentals of Cyclo Therapeutics Inc

About Cyclo Therapeutics Inc

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Fundamental data was last updated by Penke on 2024-04-11 05:43:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cyclo Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cyclo Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cyclo Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -1,812.0% means that $-18.12 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cyclo Therapeutics Inc:

  • The MRQ is -1,812.0%. The company is making a huge loss. -2
  • The TTM is -2,504.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,812.0%TTM-2,504.7%+692.8%
TTM-2,504.7%YOY20,889,147.8%-20,891,652.5%
TTM-2,504.7%5Y4,176,753.7%-4,179,258.4%
5Y4,176,753.7%10Y2,141,781.8%+2,034,971.9%
1.1.2. Return on Assets

Shows how efficient Cyclo Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cyclo Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -42.6% Return on Assets means that Cyclo Therapeutics Inc generated $-0.43 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cyclo Therapeutics Inc:

  • The MRQ is -42.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -87.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-42.6%TTM-87.5%+44.9%
TTM-87.5%YOY255,637.5%-255,725.0%
TTM-87.5%5Y51,081.4%-51,168.9%
5Y51,081.4%10Y26,182.5%+24,898.9%
1.1.3. Return on Equity

Shows how efficient Cyclo Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cyclo Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -118.6% Return on Equity means Cyclo Therapeutics Inc generated $-1.19 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cyclo Therapeutics Inc:

  • The MRQ is -118.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -29.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-118.6%TTM-29.7%-89.0%
TTM-29.7%YOY311,854.5%-311,884.2%
TTM-29.7%5Y62,339.4%-62,369.1%
5Y62,339.4%10Y31,939.4%+30,400.1%

1.2. Operating Efficiency of Cyclo Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cyclo Therapeutics Inc is operating .

  • Measures how much profit Cyclo Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cyclo Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -1,812.0% means the company generated $-18.12  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cyclo Therapeutics Inc:

  • The MRQ is -1,812.0%. The company is operating very inefficient. -2
  • The TTM is -2,502.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,812.0%TTM-2,502.9%+690.9%
TTM-2,502.9%YOY-1,436.2%-1,066.6%
TTM-2,502.9%5Y-1,357.0%-1,145.8%
5Y-1,357.0%10Y-828.1%-528.9%
1.2.2. Operating Ratio

Measures how efficient Cyclo Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 19.12 means that the operating costs are $19.12 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cyclo Therapeutics Inc:

  • The MRQ is 19.120. The company is inefficient in keeping operating costs low. -1
  • The TTM is 26.038. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ19.120TTM26.038-6.918
TTM26.038YOY15.362+10.676
TTM26.0385Y14.601+11.437
5Y14.60110Y9.298+5.303

1.3. Liquidity of Cyclo Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cyclo Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.45 means the company has $1.45 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cyclo Therapeutics Inc:

  • The MRQ is 1.455. The company is just able to pay all its short-term debts.
  • The TTM is 0.980. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ1.455TTM0.980+0.475
TTM0.980YOY3.810-2.829
TTM0.9805Y2.489-1.509
5Y2.48910Y3.328-0.840
1.3.2. Quick Ratio

Measures if Cyclo Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cyclo Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.11 means the company can pay off $1.11 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cyclo Therapeutics Inc:

  • The MRQ is 1.106. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 0.452. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ1.106TTM0.452+0.654
TTM0.452YOY2.500-2.048
TTM0.4525Y1.885-1.432
5Y1.88510Y2.570-0.685

1.4. Solvency of Cyclo Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cyclo Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cyclo Therapeutics Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.64 means that Cyclo Therapeutics Inc assets are financed with 64.1% credit (debt) and the remaining percentage (100% - 64.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cyclo Therapeutics Inc:

  • The MRQ is 0.641. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 1.064. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ0.641TTM1.064-0.423
TTM1.064YOY0.381+0.683
TTM1.0645Y0.733+0.331
5Y0.73310Y0.529+0.203
1.4.2. Debt to Equity Ratio

Measures if Cyclo Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cyclo Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 178.5% means that company has $1.78 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cyclo Therapeutics Inc:

  • The MRQ is 1.785. The company is just able to pay all its debts with equity.
  • The TTM is 0.446. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.785TTM0.446+1.339
TTM0.446YOY1.422-0.976
TTM0.4465Y0.686-0.240
5Y0.68610Y0.776-0.090

2. Market Valuation of Cyclo Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cyclo Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Cyclo Therapeutics Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -2.02 means the investor is paying $-2.02 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cyclo Therapeutics Inc:

  • The EOD is -1.603. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.023. Based on the earnings, the company is expensive. -2
  • The TTM is -1.956. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.603MRQ-2.023+0.420
MRQ-2.023TTM-1.956-0.067
TTM-1.956YOY-4.404+2.448
TTM-1.9565Y-5.131+3.174
5Y-5.13110Y-5.971+0.840
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cyclo Therapeutics Inc:

  • The EOD is -2.105. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.656. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.460. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.105MRQ-2.656+0.551
MRQ-2.656TTM-2.460-0.196
TTM-2.460YOY-4.007+1.547
TTM-2.4605Y-5.041+2.581
5Y-5.04110Y-5.788+0.748
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cyclo Therapeutics Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Cyclo Therapeutics Inc:

  • The EOD is 7.606. Based on the equity, the company is overpriced. -1
  • The MRQ is 9.598. Based on the equity, the company is overpriced. -1
  • The TTM is -28.714. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD7.606MRQ9.598-1.992
MRQ9.598TTM-28.714+38.312
TTM-28.714YOY19.543-48.257
TTM-28.7145Y1.431-30.145
5Y1.43110Y6.242-4.811
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cyclo Therapeutics Inc.

3.1. Institutions holding Cyclo Therapeutics Inc

Institutions are holding 9.757% of the shares of Cyclo Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Founders Fund V Management, LLC1.681380.7512480708-147713-23.5054
2023-12-31Vanguard Group Inc1.24240355223-77556-17.9205
2023-12-31Geode Capital Management, LLC0.531901520772724321.8234
2023-12-31Founders Fund VI Management, LLC0.38481.3724110023-33807-23.5048
2023-12-31BlackRock Inc0.1694048444-31333-39.2757
2023-12-31State Street Corporation0.1382039525-2255-5.3973
2023-12-31Wealth Enhancement Advisory Services, LLC0.06480.000118513699360.7031
2023-12-31Northern Trust Corp0.061017453-5868-25.1619
2023-09-30Citadel Advisors Llc0.0494014137-2842-16.7383
2023-12-31XTX Topco Ltd0.03740.003710696-2204-17.0853
2023-12-31Tower Research Capital LLC0.02050.00015871-1532-20.6943
2023-12-31Acadian Asset Management LLC0.00880.00012527-2643-51.1219
2023-12-31Wells Fargo & Co0.008302386130.5478
2023-12-31Royal Bank of Canada0.0026074600
2023-12-31Advisor Group Holdings, Inc.0.00210600-87-12.6638
2023-12-31Morgan Stanley - Brokerage Accounts0.00140413-1014-71.0582
2023-12-31Princeton Global Asset Management LLC0.0010.000130000
2023-12-31SIMPLEX TRADING, LLC0.000702002000
2023-12-31Qube Research & Technologies0.00040121-245-66.9399
2023-12-31New York State Common Retirement Fund0.000401131130
Total 4.406882.12771260076-274537-21.8%

3.2. Funds holding Cyclo Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv0.83690240329196018.8802
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.51020.000214652021581.4949
2024-02-29Fidelity Extended Market Index0.39710.0005114031-553-0.4826
2024-02-29Fidelity Series Total Market Index0.060601741300
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04380.000312570156914.2623
2023-12-31Northern Trust Extended Eq Market Idx0.04380.000312570-482-3.6929
2024-02-29Fidelity Total Market Index0.03160906800
2024-03-31State St US Extended Mkt Indx NL Cl C0.02570.0005737200
2023-12-31SSgA U.S. Extended Market Index Class I0.02570.00047371-299-3.8983
2024-02-29Fidelity Nasdaq Composite Index0.02430.0001697600
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.02230.00026415-580-8.2916
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.01790.00025152-455-8.1149
2024-03-31BlackRock Extended Equity Market K0.01650.0001474930.0632
2024-02-29Spartan Total Market Index Pool E0.01130324900
2024-02-29Spartan Extended Market Index Pool E0.00740.0001213955334.8676
2023-12-31SSgA U.S. Total Market Index Strategy0.00740.00012126-137-6.0539
2023-12-31Northern Trust Wilshire 50000.00450.00011297-72-5.2593
2023-12-31NT US Market Cap Idx Fd - L0.00450.00011297-72-5.2593
2024-03-31BlackRock U.S. Equity Market F0.0024069681.1628
2024-02-29BlackRock Advantage Small Cap Core Instl0.0022062300
Total 2.09610.0032601963+21242+3.5%

3.3. Insider Transactions

Insiders are holding 41.271% of the shares of Cyclo Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-01Rafael Holdings, Inc.BUY40000001.25
2023-04-20Jeffrey TateBUY299410.71
2023-04-20Markus SiegerBUY598810.71
2023-04-20N Scott FineBUY2994020.71

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cyclo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2020.035+478%-0.130+164%0.007+2987%0.003+7550%
Book Value Per Share--0.1660.016+969%0.254-35%0.164+1%0.129+29%
Current Ratio--1.4550.980+48%3.810-62%2.489-42%3.328-56%
Debt To Asset Ratio--0.6411.064-40%0.381+68%0.733-13%0.529+21%
Debt To Equity Ratio--1.7850.446+300%1.422+26%0.686+160%0.776+130%
Dividend Per Share----0%-0%-0%-0%
Eps---0.196-0.175-11%-0.135-32%-0.115-41%-0.072-63%
Free Cash Flow Per Share---0.150-0.141-6%-0.132-12%-0.107-29%-0.065-56%
Free Cash Flow To Equity Per Share--0.2590.067+287%-0.131+151%0.016+1538%0.010+2618%
Gross Profit Margin--1.0001.000+0%1.0010%1.0010%1.0020%
Intrinsic Value_10Y_max---4.772--------
Intrinsic Value_10Y_min---6.194--------
Intrinsic Value_1Y_max---0.293--------
Intrinsic Value_1Y_min---0.555--------
Intrinsic Value_3Y_max---1.021--------
Intrinsic Value_3Y_min---1.735--------
Intrinsic Value_5Y_max---1.920--------
Intrinsic Value_5Y_min---2.978--------
Market Cap36181782.000-26%45657963.00039054069.893+17%60949073.250-25%70846657.148-36%43793209.620+4%
Net Profit Margin---18.120-25.047+38%208891.478-100%41767.537-100%21417.818-100%
Operating Margin---18.120-25.029+38%-14.362-21%-13.570-25%-8.281-54%
Operating Ratio--19.12026.038-27%15.362+24%14.601+31%9.298+106%
Pb Ratio7.606-26%9.598-28.714+399%19.543-51%1.431+571%6.242+54%
Pe Ratio-1.603+21%-2.023-1.956-3%-4.404+118%-5.131+154%-5.971+195%
Price Per Share1.260-26%1.5901.360+17%2.123-25%2.467-36%1.525+4%
Price To Free Cash Flow Ratio-2.105+21%-2.656-2.460-7%-4.007+51%-5.041+90%-5.788+118%
Price To Total Gains Ratio6.228-26%7.8599.500-17%-18.395+334%-6.585+184%-6.146+178%
Quick Ratio--1.1060.452+145%2.500-56%1.885-41%2.570-57%
Return On Assets---0.426-0.875+105%2556.375-100%510.814-100%261.825-100%
Return On Equity---1.186-0.297-75%3118.545-100%623.394-100%319.394-100%
Total Gains Per Share--0.2020.035+478%-0.130+164%0.007+2987%0.003+7550%
Usd Book Value--4757007.000445156.500+969%7283765.000-35%4722495.300+1%3701684.744+29%
Usd Book Value Change Per Share--0.2020.035+478%-0.130+164%0.007+2987%0.003+7550%
Usd Book Value Per Share--0.1660.016+969%0.254-35%0.164+1%0.129+29%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.196-0.175-11%-0.135-32%-0.115-41%-0.072-63%
Usd Free Cash Flow---4297302.000-4046861.500-6%-3778560.250-12%-3071832.850-29%-1875004.692-56%
Usd Free Cash Flow Per Share---0.150-0.141-6%-0.132-12%-0.107-29%-0.065-56%
Usd Free Cash Flow To Equity Per Share--0.2590.067+287%-0.131+151%0.016+1538%0.010+2618%
Usd Market Cap36181782.000-26%45657963.00039054069.893+17%60949073.250-25%70846657.148-36%43793209.620+4%
Usd Price Per Share1.260-26%1.5901.360+17%2.123-25%2.467-36%1.525+4%
Usd Profit---5642409.000-5014302.000-11%40712681036.000-100%8139995307.250-100%4173981105.077-100%
Usd Revenue--311399.000269101.250+16%343940.000-9%297424.750+5%308216.872+1%
Usd Total Gains Per Share--0.2020.035+478%-0.130+164%0.007+2987%0.003+7550%
 EOD+2 -6MRQTTM+23 -11YOY+9 -255Y+13 -2110Y+14 -20

4.2. Fundamental Score

Let's check the fundamental score of Cyclo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.603
Price to Book Ratio (EOD)Between0-17.606
Net Profit Margin (MRQ)Greater than0-18.120
Operating Margin (MRQ)Greater than0-18.120
Quick Ratio (MRQ)Greater than11.106
Current Ratio (MRQ)Greater than11.455
Debt to Asset Ratio (MRQ)Less than10.641
Debt to Equity Ratio (MRQ)Less than11.785
Return on Equity (MRQ)Greater than0.15-1.186
Return on Assets (MRQ)Greater than0.05-0.426
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Cyclo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.614
Ma 20Greater thanMa 501.304
Ma 50Greater thanMa 1001.483
Ma 100Greater thanMa 2001.548
OpenGreater thanClose1.330
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  171-29142-4597360457-1,022-565



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets13,248
Total Liabilities8,491
Total Stockholder Equity4,757
 As reported
Total Liabilities 8,491
Total Stockholder Equity+ 4,757
Total Assets = 13,248

Assets

Total Assets13,248
Total Current Assets12,318
Long-term Assets929
Total Current Assets
Cash And Cash Equivalents 9,247
Net Receivables 122
Inventory 254
Other Current Assets 2,695
Total Current Assets  (as reported)12,318
Total Current Assets  (calculated)12,318
+/-0
Long-term Assets
Property Plant Equipment 929
Long-term Assets  (as reported)929
Long-term Assets  (calculated)929
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,468
Long-term Liabilities22
Total Stockholder Equity4,757
Total Current Liabilities
Short-term Debt 1,011
Accounts payable 4,857
Other Current Liabilities 2,601
Total Current Liabilities  (as reported)8,468
Total Current Liabilities  (calculated)8,468
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt22
Long-term Liabilities  (as reported)22
Long-term Liabilities  (calculated)22
+/-0
Total Stockholder Equity
Common Stock3
Retained Earnings -83,857
Other Stockholders Equity 88,611
Total Stockholder Equity (as reported)4,757
Total Stockholder Equity (calculated)4,757
+/-0
Other
Capital Stock3
Cash and Short Term Investments 9,247
Common Stock Shares Outstanding 24,869
Liabilities and Stockholders Equity 13,248
Net Debt -8,213
Net Invested Capital 4,757
Net Working Capital 3,850
Property Plant and Equipment Gross 1,050
Short Long Term Debt Total 1,033



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-09-302007-06-302007-03-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-09-302001-06-302001-03-312000-09-30
> Total Assets 
813
552
551
486
468
523
552
490
476
493
528
863
918
959
991
1,010
1,060
1,042
1,067
764
845
783
753
760
861
987
1,599
1,433
1,523
1,231
1,247
1,252
1,307
1,295
1,323
1,372
1,820
1,932
2,262
2,385
2,515
2,790
2,824
2,712
2,667
2,618
2,798
2,952
2,843
2,789
3,362
4,051
5,618
5,285
4,905
4,488
5,841
4,757
4,031
4,972
3,234
1,869
2,678
2,195
2,170
2,089
2,292
1,871
2,918
1,905
7,591
5,862
4,113
2,286
2,262
4,132
14,188
18,141
14,243
11,097
19,521
15,924
11,842
8,488
4,215
4,097
4,643
5,597
13,248
13,2485,5974,6434,0974,2158,48811,84215,92419,52111,09714,24318,14114,1884,1322,2622,2864,1135,8627,5911,9052,9181,8712,2922,0892,1702,1952,6781,8693,2344,9724,0314,7575,8414,4884,9055,2855,6184,0513,3622,7892,8432,9522,7982,6182,6672,7122,8242,7902,5152,3852,2621,9321,8201,3721,3231,2951,3071,2521,2471,2311,5231,4331,5999878617607537838457641,0671,0421,0601,010991959918863528493476490552523468486551552813
   > Total Current Assets 
171
98
133
88
78
173
208
147
131
128
154
269
310
233
256
272
313
299
334
278
364
287
255
322
435
547
581
509
591
516
515
518
578
565
510
350
320
366
625
452
269
316
397
287
275
304
558
828
662
619
1,226
1,840
3,379
3,049
2,552
2,114
3,524
2,523
1,873
2,869
2,019
1,636
2,457
1,983
1,965
1,896
2,121
1,711
2,770
1,688
7,403
5,690
3,958
2,097
2,088
3,972
14,050
18,021
14,121
10,992
19,436
15,850
11,777
8,422
4,159
3,993
4,548
5,512
12,318
12,3185,5124,5483,9934,1598,42211,77715,85019,43610,99214,12118,02114,0503,9722,0882,0973,9585,6907,4031,6882,7701,7112,1211,8961,9651,9832,4571,6362,0192,8691,8732,5233,5242,1142,5523,0493,3791,8401,226619662828558304275287397316269452625366320350510565578518515516591509581547435322255287364278334299313272256233310269154128131147208173788813398171
       Cash And Cash Equivalents 
0
17
1
5
8
27
77
46
36
51
63
8
106
57
101
94
157
48
66
31
37
37
14
24
43
25
210
207
243
277
261
239
279
339
252
131
9
107
349
142
25
127
26
46
85
23
98
532
540
269
873
1,491
2,744
2,380
1,847
1,427
2,742
1,842
1,079
2,134
1,270
960
1,638
1,331
1,343
1,271
1,541
1,122
2,217
1,115
6,608
4,994
2,784
933
1,008
2,238
12,846
15,507
11,463
8,441
16,613
11,799
7,453
4,290
1,543
915
842
1,802
9,247
9,2471,8028429151,5434,2907,45311,79916,6138,44111,46315,50712,8462,2381,0089332,7844,9946,6081,1152,2171,1221,5411,2711,3431,3311,6389601,2702,1341,0791,8422,7421,4271,8472,3802,7441,491873269540532982385462612725142349107913125233927923926127724320721025432414373731664815794101571068635136467727851170
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41
129
130
156
158
78
154
136
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000001000013615478158156130129410000000000000000
       Net Receivables 
75
9
83
33
36
108
57
36
25
9
16
134
47
90
30
59
22
40
57
36
65
75
30
59
28
78
85
56
47
28
43
65
97
40
74
42
124
79
111
210
110
46
211
69
14
65
251
171
16
99
60
40
173
81
39
49
114
56
135
108
151
124
257
136
128
93
127
107
117
112
192
73
182
208
200
125
112
220
224
400
539
158
439
395
55
131
88
304
122
1223048813155395439158539400224220112125200208182731921121171071279312813625712415110813556114493981173406099161712516514692114611021011179124427440976543284756857828593075653657402259309047134169253657108363383975
       Inventory 
61
56
47
47
32
38
74
64
69
69
75
79
78
56
57
51
67
57
55
55
98
97
53
80
95
105
108
169
224
210
210
211
201
185
181
175
185
175
165
100
132
142
159
172
175
205
201
115
101
241
260
278
429
575
622
608
646
610
621
617
595
497
500
473
474
471
408
437
417
413
398
384
243
229
217
421
238
258
269
254
227
221
261
271
254
244
237
210
254
25421023724425427126122122725426925823842121722924338439841341743740847147447350049759561762161064660862257542927826024110111520120517517215914213210016517518517518118520121121021022416910810595805397985555576751575678797569696474383247475661
       Other Current Assets 
36
17
3
3
1
0
0
0
0
0
0
23
3
3
43
42
2
0
0
0
7
0
4
24
259
337
3
2
2
2
2
2
2
0
3
2
2
5
1
1
1
1
1
1
1
11
9
10
5
10
33
30
34
13
44
30
21
15
37
11
2
54
62
43
20
61
45
45
18
47
207
238
749
727
663
1,189
854
2,036
2,164
1,897
2,057
3,712
3,624
3,466
2,306
2,703
3,381
3,196
2,695
2,6953,1963,3812,7032,3063,4663,6243,7122,0571,8972,1642,0368541,189663727749238207471845456120436254211371521304413343033105109111111111522302222223337259244070002424333230000001331736
   > Long-term Assets 
642
454
418
398
391
351
344
343
345
365
374
594
608
725
736
738
747
743
733
486
482
497
498
438
427
440
1,017
925
932
715
732
734
729
731
813
1,022
1,500
1,565
1,637
1,933
2,246
2,474
2,427
2,426
2,392
2,314
2,239
2,124
2,181
2,171
2,136
2,211
2,239
2,236
2,353
2,374
2,317
2,234
2,158
2,102
1,215
233
221
212
205
193
172
160
148
218
188
173
155
189
174
160
138
120
123
104
84
74
65
66
57
104
95
86
929
929869510457666574841041231201381601741891551731882181481601721932052122212331,2152,1022,1582,2342,3172,3742,3532,2362,2392,2112,1362,1712,1812,1242,2392,3142,3922,4262,4272,4742,2461,9331,6371,5651,5001,0228137317297347327159329251,017440427438498497482486733743747738736725608594374365345343344351391398418454642
       Property Plant Equipment 
436
418
394
394
387
347
341
335
337
357
371
379
396
406
421
431
442
438
429
424
420
422
423
334
414
417
437
448
446
443
460
467
465
467
548
758
1,255
1,331
1,393
1,691
1,509
1,722
1,694
1,676
1,643
1,608
1,575
1,541
1,571
1,627
1,649
1,655
1,648
1,646
1,764
1,786
1,855
1,893
1,857
1,810
34
30
26
26
27
26
22
20
19
82
76
71
65
108
103
96
88
81
94
86
77
74
65
66
57
104
95
86
929
929869510457666574778694818896103108657176821920222627262630341,8101,8571,8931,8551,7861,7641,6461,6481,6551,6491,6271,5711,5411,5751,6081,6431,6761,6941,7221,5091,6911,3931,3311,255758548467465467460443446448437417414334423422420424429438442431421406396379371357337335341347387394394418436
       Intangible Assets 
26
25
24
4
4
3
3
3
3
3
3
14
14
14
13
13
12
12
12
12
12
11
11
10
12
22
41
85
90
5
5
5
4
4
4
4
10
10
18
17
16
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000001617181010444455590854122121011111212121212131314141433333344242526
       Long-term Assets Other 
180
11
0
0
0
0
0
5
5
5
0
0
0
106
101
94
92
92
92
50
50
63
65
94
0
2
164
0
4
17
17
13
10
10
11
10
10
235
0
0
496
527
526
525
524
506
505
513
520
423
422
422
471
470
469
468
342
341
301
292
1,182
203
195
186
177
167
149
140
130
135
111
102
91
81
71
65
50
39
28
19
7
74
-65
-66
-57
-104
-95
41
0
041-95-104-57-66-6574719283950657181911021111351301401491671771861952031,18229230134134246846947047142242242352051350550652452552652749600235101011101013171740164209465635050929292941011060005550000011180
> Total Liabilities 
432
463
445
422
438
386
327
293
291
288
295
297
318
492
497
442
268
205
194
186
266
199
193
200
159
164
235
58
74
72
86
65
40
94
65
65
527
529
869
955
1,052
1,366
1,353
1,298
1,249
1,070
1,129
1,020
964
994
1,008
908
1,008
915
907
850
1,040
1,012
991
1,123
876
343
221
566
1,130
943
1,289
1,655
1,925
2,687
2,751
2,379
3,177
3,984
4,182
4,657
3,735
3,820
3,117
3,469
3,849
2,876
2,102
2,875
3,481
4,536
6,128
6,650
8,491
8,4916,6506,1284,5363,4812,8752,1022,8763,8493,4693,1173,8203,7354,6574,1823,9843,1772,3792,7512,6871,9251,6551,2899431,1305662213438761,1239911,0121,0408509079151,0089081,0089949641,0201,1291,0701,2491,2981,3531,3661,052955869529527656594406586727458235164159200193199266186194205268442497492318297295288291293327386438422445463432
   > Total Current Liabilities 
253
227
291
269
180
119
72
32
40
40
62
76
92
263
256
256
98
56
47
38
119
54
49
58
20
28
78
58
74
72
86
65
40
28
65
65
99
103
134
227
332
652
596
553
516
319
430
257
154
199
226
141
259
915
907
850
1,040
1,012
991
1,123
876
343
221
566
1,130
943
1,289
1,655
1,925
2,637
2,705
2,337
3,141
3,952
4,057
4,560
3,673
3,707
3,035
3,420
3,831
2,876
2,102
2,875
3,481
4,500
6,096
6,622
8,468
8,4686,6226,0964,5003,4812,8752,1022,8763,8313,4203,0353,7073,6734,5604,0573,9523,1412,3372,7052,6371,9251,6551,2899431,1305662213438761,1239911,0121,040850907915259141226199154257430319516553596652332227134103996565284065867274587828205849541193847569825625626392766240403272119180269291227253
       Short-term Debt 
52
45
41
40
28
8
8
9
9
22
32
30
30
30
30
28
28
42
21
10
6
6
6
6
6
6
4
0
0
0
0
0
0
0
0
0
13
13
26
26
88
123
139
139
139
235
249
145
95
56
77
56
60
794
780
765
750
754
709
689
608
0
0
0
0
0
0
0
0
14
14
14
16
17
78
102
132
78
105
126
153
15
10
5
0
17
17
18
1,011
1,0111817170510151531261057813210278171614141400000000608689709754750765780794605677569514524923513913913912388262613130000000004666666102142282830303030322299882840414552
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
61
87
114
60
87
107
134
0
0
0
0
0
0
0
0
000000001341078760114876100000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
188
182
168
137
152
111
64
23
31
18
30
46
62
26
21
24
31
14
26
28
113
48
43
52
14
21
74
58
74
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
343
221
566
545
943
1,289
1,655
1,925
2,623
0
0
3,125
3,936
3,979
4,458
3,541
3,628
2,930
3,294
3,678
2,862
2,092
2,870
3,481
4,483
6,078
6,605
4,857
4,8576,6056,0784,4833,4812,8702,0922,8623,6783,2942,9303,6283,5414,4583,9793,9363,125002,6231,9251,6551,2899435455662213430000000000000000000000000000000074587421145243481132826143124212662463018312364111152137168182188
       Other Current Liabilities 
13
79
82
92
0
0
0
0
0
0
0
0
0
207
205
203
38
0
0
0
0
0
0
2
1
0
0
0
0
72
86
65
40
28
65
65
87
90
109
201
244
529
457
414
377
84
181
112
60
143
149
85
199
121
127
85
290
258
282
434
268
0
0
0
585
75
0
0
0
14
2,691
2,323
3,125
3,936
3,979
4,458
3,541
3,628
3,017
3,294
3,678
2,862
2,092
2,870
0
4,483
6,078
6,605
2,601
2,6016,6056,0784,48302,8702,0922,8623,6783,2943,0173,6283,5414,4583,9793,9363,1252,3232,6911400075585000268434282258290851271211998514914360112181843774144575292442011099087656528406586720000120000003820320520700000000092827913
   > Long-term Liabilities 
179
236
154
152
257
268
255
261
251
248
233
221
226
229
240
186
170
149
147
149
147
145
144
142
139
137
157
0
0
0
0
0
0
66
0
0
427
426
735
729
721
713
757
745
733
751
699
763
809
795
781
767
749
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
46
42
36
32
125
97
63
113
82
50
18
2,876
2,102
2,875
3,481
37
32
27
22
222732373,4812,8752,1022,8761850821136397125323642465000000000000000007497677817958097636997517337457577137217297354264270066000000157137139142144145147149147149170186240229226221233248251261255268257152154236179
> Total Stockholder Equity
381
89
106
64
31
137
225
196
185
205
233
566
599
466
495
568
791
837
873
578
579
584
561
560
702
823
1,364
1,376
1,449
1,159
1,161
1,188
1,267
1,202
1,257
1,307
1,293
1,403
1,393
1,430
1,462
1,424
1,470
1,414
1,418
1,549
1,669
1,932
1,879
1,795
2,354
3,143
4,610
4,370
3,998
3,638
4,801
3,746
3,040
3,849
2,358
1,526
2,457
1,629
1,040
1,146
1,003
216
993
-782
4,840
3,483
936
-1,698
-1,920
-525
10,452
14,322
11,126
7,627
15,672
13,048
9,740
5,612
735
-439
-1,485
-1,053
4,757
4,757-1,053-1,485-4397355,6129,74013,04815,6727,62711,12614,32210,452-525-1,920-1,6989363,4834,840-7829932161,0031,1461,0401,6292,4571,5262,3583,8493,0403,7464,8013,6383,9984,3704,6103,1432,3541,7951,8791,9321,6691,5491,4181,4141,4701,4241,4621,4301,3931,4031,2931,3071,2571,2021,2671,1881,1611,1591,4491,3761,364823702560561584579578873837791568495466599566233205185196225137316410689381
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
6
6
6
7
7
7
7
7
7
7
9
9
9
9
12
12
12
12
14
17
0
1
1
1
1
1
1
1
1
1
2
2
3
32211111111101714121212129999777777766655555544444444444443333333322222221111111111100000000000
   Retained Earnings -83,857-78,214-73,443-68,806-63,799-58,819-54,572-51,120-48,348-45,556-41,696-38,098-34,062-31,382-29,947-27,754-25,120-22,485-20,860-19,492-17,588-16,222-15,435-13,333-11,949-11,315-10,487-9,500-8,668-7,053-5,982-5,276-4,220-3,473-3,113-2,724-2,407-2,186-2,035-2,132-2,047-1,953-2,217-2,337-2,467-2,421-2,365-2,411-2,270-2,288-2,323-2,313-2,378-2,341-2,367-2,276-2,113-2,146-2,135-2,082-1,744-1,745-1,669-2,164-2,234-2,323-2,322-2,260-2,241-2,221-1,901-1,826-1,848-2,048-1,803-1,814-1,471-1,464-1,722-1,749-1,770-1,759-1,730-1,818-1,924-1,891-1,838-1,810-1,503
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
71,957
0
0
0071,95700000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
1,884
1,899
1,943
1,954
1,954
1,954
1,954
1,954
1,954
1,954
1,954
2,029
2,069
2,280
2,297
2,615
2,638
2,662
2,773
2,797
2,819
2,842
2,881
2,881
2,935
2,985
3,031
3,119
3,190
3,239
3,293
3,331
3,378
3,474
3,621
3,645
3,668
3,712
3,713
3,714
3,729
3,832
3,832
3,832
3,882
3,882
3,882
3,882
3,923
3,923
4,384
5,324
7,012
7,089
7,105
7,105
9,016
9,016
9,016
10,895
11,019
11,019
12,936
12,936
12,981
14,471
16,430
16,430
18,571
18,701
25,688
25,956
26,044
26,044
28,012
30,841
44,514
52,419
52,821
53,183
64,020
64,167
64,311
64,431
64,533
68,367
71,957
77,160
88,611
88,61177,16071,95768,36764,53364,43164,31164,16764,02053,18352,82152,41944,51430,84128,01226,04426,04425,95625,68818,70118,57116,43016,43014,47112,98112,93612,93611,01911,01910,8959,0169,0169,0167,1057,1057,0897,0125,3244,3843,9233,9233,8823,8823,8823,8823,8323,8323,8323,7293,7143,7133,7123,6683,6453,6213,4743,3783,3313,2933,2393,1903,1193,0312,9852,9352,8812,8812,8422,8192,7972,7732,6622,6382,6152,2972,2802,0692,0291,9541,9541,9541,9541,9541,9541,9541,9541,9431,8991,884



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,076
Cost of Revenue-3,487
Gross Profit-2,410-2,410
 
Operating Income (+$)
Gross Profit-2,410
Operating Expense-17,640
Operating Income-20,050-20,050
 
Operating Expense (+$)
Research Development14,182
Selling General Administrative5,662
Selling And Marketing Expenses4
Operating Expense17,64019,848
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-20,050
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-20,057-20,043
EBIT - interestExpense = -20,050
-20,057
-20,057
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-20,050-20,057
Earnings Before Interest and Taxes (EBITDA)-20,031
 
After tax Income (+$)
Income Before Tax-20,057
Tax Provision-0
Net Income From Continuing Ops-19,395-20,057
Net Income-20,057
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses21,126
Total Other Income/Expenses Net-70
 

Technical Analysis of Cyclo Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cyclo Therapeutics Inc. The general trend of Cyclo Therapeutics Inc is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cyclo Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cyclo Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.32 < 1.41 < 1.45.

The bearish price targets are: 1.15 > 1.15 > 1.1308.

Tweet this
Cyclo Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cyclo Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cyclo Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cyclo Therapeutics Inc. The current macd is -0.06720372.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cyclo Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cyclo Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cyclo Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cyclo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCyclo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cyclo Therapeutics Inc. The current adx is 16.77.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cyclo Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Cyclo Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cyclo Therapeutics Inc. The current sar is 1.49072998.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cyclo Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cyclo Therapeutics Inc. The current rsi is 42.61. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Cyclo Therapeutics Inc Daily Relative Strength Index (RSI) ChartCyclo Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cyclo Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cyclo Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cyclo Therapeutics Inc Daily Stochastic Oscillator ChartCyclo Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cyclo Therapeutics Inc. The current cci is -12.93793225.

Cyclo Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCyclo Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cyclo Therapeutics Inc. The current cmo is -10.08540482.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cyclo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCyclo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cyclo Therapeutics Inc. The current willr is -54.28571429.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cyclo Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cyclo Therapeutics Inc Daily Williams %R ChartCyclo Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cyclo Therapeutics Inc. The current atr is 0.11557451.

Cyclo Therapeutics Inc Daily Average True Range (ATR) ChartCyclo Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cyclo Therapeutics Inc. The current obv is 5,653,616.

Cyclo Therapeutics Inc Daily On-Balance Volume (OBV) ChartCyclo Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cyclo Therapeutics Inc. The current mfi is 42.82.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cyclo Therapeutics Inc Daily Money Flow Index (MFI) ChartCyclo Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cyclo Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-26STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Cyclo Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cyclo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.614
Ma 20Greater thanMa 501.304
Ma 50Greater thanMa 1001.483
Ma 100Greater thanMa 2001.548
OpenGreater thanClose1.330
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cyclo Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Cyclo Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cyclo Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cyclo Therapeutics Inc

I send you an email if I find something interesting about Cyclo Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cyclo Therapeutics Inc.

Receive notifications about Cyclo Therapeutics Inc in your mailbox!